Recently, it is the disclosure period of the performance of major pharmaceutical companies in the first half of 2022
.
Up to now, hundreds of pharmaceutical companies have disclosed their semi-annual reports.
On the whole, nearly 50% of them have achieved a year-on-year increase in net profit
.
While the performance of pharmaceutical companies continues to improve, R&D investment is also increasing (Source: Pharmaceutical Network)
While the performance of pharmaceutical companies continues to improve, R&D investment is also increasing
While the performance of pharmaceutical companies continues to improve, R&D investment is also increasing
On August 10, the 2022 semi-annual report released by Huadong Medicine showed that the company achieved operating income of 18.
197 billion yuan in the first half of the year, a year-on-year increase of 5.
93%; net profit attributable to shareholders of listed companies was 1.
34 billion yuan, a year-on-year increase of 3.
09%; attributable to listed companies Shareholders deducted non-net profit of 1.
272 billion yuan, a year-on-year increase of 6.
52%
.
On August 9, Qianhong Pharmaceutical released its performance report for the first half of 2022.
During the reporting period, the company achieved operating income of 1.
14 billion yuan, a year-on-year increase of 30.
23%; The net profit after that was 202 million yuan and 147 million yuan respectively, an increase of 126.
42% and 79.
21% year-on-year respectively
.
On August 8, Zhongsheng Pharmaceutical released its 2022 semi-annual report.
In the first half of the year, it achieved an operating income of 1.
326 billion yuan and a non-net profit of 188 million yuan attributable to the parent
.
It is worth noting that while a large number of pharmaceutical companies have ushered in new growth in performance, their R&D investment has continued to increase
.
It is understood that the R&D investment of Zhongsheng Pharmaceutical in the first half of the year reached 80.
4389 million yuan, a year-on-year increase of 21.
25%
.
In addition, Kangchen Pharmaceuticals, at the second extraordinary general meeting in 2022, reviewed and decided to reduce the raised funds of "innovative drug research and development and targeted anti-tumor drug innovation platform construction projects" by 320 million yuan, accounting for 34.
99% of the net raised funds.
% for the research and development of the new fundraising project KC1036
.
Industry analysts believe that increasing investment in R&D has important strategic significance for the medium and long-term development of enterprises.
Therefore, at present, powerful pharmaceutical companies are increasing R&D investment to accelerate innovation and promote high-quality development of enterprises
.
With the continuous R&D investment of a large number of pharmaceutical companies, the innovation of China's pharmaceutical industry may be expected to accelerate in the future
.
In fact, according to data, as of the beginning of this year, China's drug research and development volume has accounted for 20.
8% of the world's
.
Obviously, China's pharmaceutical R&D has entered a period of vigorous development
.
Pharmaceutical machine companies are also increasing investment in research and development
Pharmaceutical machine companies are also increasing investment in research and development
At present, in addition to pharmaceutical companies, there are also many companies in other fields of the pharmaceutical industry that are continuously increasing their investment in innovative research and development
.
Among them, the pharmaceutical machinery and equipment industry has performed very well in research and development in recent years, especially many listed pharmaceutical equipment companies are very "generous" in research and development and innovation
.
Among them, Tofflon's R&D investment in 2020 has reached 156 million yuan, accounting for 5.
77% of operating income
.
The research and development expenses in the first three quarters of 2021 are 166 million yuan, which has exceeded the research and development expenses for the whole year of last year
.
At present, it is making great efforts to accelerate innovative research and development and increase production capacity.
On July 13 this year, Tofflon released the "Announcement on the Company's Issue of Shares to Specific Objects and Obtained the Review and Approval of the Shenzhen Stock Exchange Listing Review Center", and plans to raise additional funds.
No more than 3.
2 billion, it is planned to be used for the biopharmaceutical equipment industry trial production center project, the Jiangsu biomedical equipment industrialization base project, and the life science industrialization base project of Zhejiang Tofflon Biotechnology Co.
, Ltd.
to supplement working capital
.
When Canaan Technology released its 2022 first quarter performance forecast, it said that the company will continue to increase its efforts to develop new markets and invest in new product research and development, strengthen brand effects and marketing network channel construction, and improve product quality.
Steady development has ensured steady growth in operating performance, resulting in an increase in the company's net profit
.
Epilogue
Epilogue
Industry analysts believe that the above-mentioned pharmaceutical machine companies can see the development status and trends of the domestic pharmaceutical equipment industry from the actions of the above-mentioned pharmaceutical machine companies: the driving force for the development of innovative pharmaceutical machine companies has become a consensus
.
In the future, pharmaceutical machine companies are expected to accelerate the research and development of more new technologies, new products, innovate, improve and upgrade existing equipment according to the needs of the industry and customers, so as to promote the accelerated development of the industry in the direction of high quality
.
